HAEM4Backup:ALK-Positive Large B-cell Lymphoma
![]() | This page is under construction |
Primary Author(s)*
Manando Nakasaki, MD, PhD (University of California, Irvine)
Fabiola Quintero-Rivera, MD, FACMG (University of California, Irvine)
Cancer Category/Type
Mature B cell neoplasm
Cancer Sub-Classification / Subtype
Large B-cell lymphomas
Definition / Description of Disease
Diffuse, monomorphic neoplasm of large B-cells with a plasmablastic immunophenotype and ALK expression due to ALK rearrangement
Synonyms / Terminology
Not recommended: ALK-positive plasmablastic B-cell lymphoma; ALK-positive diffuse large B-cell lymphoma
Epidemiology / Prevalence
- <1% of large B-cell lymphomas
- ~ 200 cases reported in literature to date[1]
Clinical Features
Signs and Symptoms | Asymptomatic lymphadenopathy
B-symptoms |
Laboratory Findings | Serum LDH elevation |
Sites of Involvement
- Lymph nodes are most commonly involved (~ 75%)
- Extranodal sites: bone marrow, GI tract, liver, epidural space, ovaries, skeletal system, nasopharyngeal/nasal area, tongue, and brain[6][7][8]
Morphologic Features
- Partial or diffuse effacement of lymph node architecture
- Lymphoma cells infiltrate sinusoids[9][10]
- Monomorphic infiltrate of large cells with abundant amphophilic or eosinophilic cytoplasm
Immunophenotype
Finding | Marker |
---|---|
Positive (universal) | ALK, CD138, VS38, IRF4/MUM1, BLIMP1, XBP1 |
Positive (subset) | EMA (90%), Cytoplasmic Ig (90%), IgA (80%), CD45 (90%), CD30 (15%), CD4 (50%), CD57 (10%), CD43, Cytokeratin (10%) |
Negative (universal) | Pan-T cell antigens, CD8, B-cell antigens, CD10, BCL-6, Cyclin-D1, HHV8 |
Chromosomal Rearrangements (Gene Fusions)
Chromosomal Rearrangement | Genes in Fusion (5’ or 3’ Segments) | ALK Immunostain Pattern | Prevalence | Notes |
---|---|---|---|---|
t(2;17)(p23;q23) | CLTC::ALK | Cytoplasmic; granular | Most common | [11] |
t(2;5)(p23;q35) | NPM::ALK | Nuclear and cytoplasmic | [12] | |
t(2;5)(p23;q35.3) | SQSTM1::ALK | Cytoplasmic; diffuse | [13] | |
inv(2)(p23q13) or t(2;2)(p23;q13) | RANBP2::ALK | Nuclear membrane and perinuclear punctate | [14] | |
inv(2)(p21p23) | EML4::ALK | Cytoplasmic; diffuse | [15] | |
inv(2)(p21q31.1) or t(2;2)(p23;q31.1) | GORASP2::ALK | Cytoplasmic; diffuse | [16] | |
Cryptic | SEC31A::ALK | Cytoplasmic; granular | [17] |
Individual Region Genomic Gain/Loss/LOH
Gains or amplifications of MYC (~50% of cases)[18]
Characteristic Chromosomal Patterns
N/A
Gene Mutations (SNV/INDEL)
N/A
Epigenomic Alterations
N/A
Genes and Main Pathways Involved
Gene; Genetic Alteration | Pathway | Pathophysiologic Outcome |
---|---|---|
ALK rearrangement; Activating fusions | JAK/STAT, PI3K/AKT, MAPK/ERK and phospholipase C gamma 2 (PLCG2) pathways | Transformation, increased growth and inhibition of apoptosis |
Genetic Diagnostic Testing Methods
- Detection of ALK rearrangement by NGS or FISH
- Monoclonal IGH rearrangements by PCR
Familial Forms
N/A
Additional Information
N/A
Links
N/A
References
- ↑ Castillo, Jorge J.; et al. (2021-12). "Anaplastic lymphoma kinase-positive large B-cell lymphoma (ALK + LBCL): a systematic review of clinicopathological features and management". Leukemia & Lymphoma. 62 (12): 2845–2853. doi:10.1080/10428194.2021.1941929. ISSN 1029-2403. PMID 34151703 Check
|pmid=
value (help). Check date values in:|date=
(help) - ↑ Pan, Zenggang; et al. (2017-01). "ALK-positive Large B-cell Lymphoma: A Clinicopathologic Study of 26 Cases With Review of Additional 108 Cases in the Literature". The American Journal of Surgical Pathology. 41 (1): 25–38. doi:10.1097/PAS.0000000000000753. ISSN 1532-0979. PMID 27740969. Check date values in:
|date=
(help) - ↑ Castillo, Jorge J.; et al. (2021-12). "Anaplastic lymphoma kinase-positive large B-cell lymphoma (ALK + LBCL): a systematic review of clinicopathological features and management". Leukemia & Lymphoma. 62 (12): 2845–2853. doi:10.1080/10428194.2021.1941929. ISSN 1029-2403. PMID 34151703 Check
|pmid=
value (help). Check date values in:|date=
(help) - ↑ Sukswai, Narittee; et al. (2020-01). "Diffuse large B-cell lymphoma variants: an update". Pathology. 52 (1): 53–67. doi:10.1016/j.pathol.2019.08.013. ISSN 1465-3931. PMID 31735345. Check date values in:
|date=
(help) - ↑ Castillo, Jorge J.; et al. (2021-12). "Anaplastic lymphoma kinase-positive large B-cell lymphoma (ALK + LBCL): a systematic review of clinicopathological features and management". Leukemia & Lymphoma. 62 (12): 2845–2853. doi:10.1080/10428194.2021.1941929. ISSN 1029-2403. PMID 34151703 Check
|pmid=
value (help). Check date values in:|date=
(help) - ↑ Morgan, Elizabeth A.; et al. (2012). "Anaplastic lymphoma kinase-positive large B-cell lymphoma: an underrecognized aggressive lymphoma". Advances in Hematology. 2012: 529572. doi:10.1155/2012/529572. ISSN 1687-9112. PMC 3299366. PMID 22474449.
- ↑ Pan, Zenggang; et al. (2017-01). "ALK-positive Large B-cell Lymphoma: A Clinicopathologic Study of 26 Cases With Review of Additional 108 Cases in the Literature". The American Journal of Surgical Pathology. 41 (1): 25–38. doi:10.1097/PAS.0000000000000753. ISSN 1532-0979. PMID 27740969. Check date values in:
|date=
(help) - ↑ Laurent, Camille; et al. (2009-09-01). "Anaplastic lymphoma kinase-positive diffuse large B-cell lymphoma: a rare clinicopathologic entity with poor prognosis". Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 27 (25): 4211–4216. doi:10.1200/JCO.2008.21.5020. ISSN 1527-7755. PMID 19636007.
- ↑ Pan, Zenggang; et al. (2017-01). "ALK-positive Large B-cell Lymphoma: A Clinicopathologic Study of 26 Cases With Review of Additional 108 Cases in the Literature". The American Journal of Surgical Pathology. 41 (1): 25–38. doi:10.1097/PAS.0000000000000753. ISSN 1532-0979. PMID 27740969. Check date values in:
|date=
(help) - ↑ Sukswai, Narittee; et al. (2020-01). "Diffuse large B-cell lymphoma variants: an update". Pathology. 52 (1): 53–67. doi:10.1016/j.pathol.2019.08.013. ISSN 1465-3931. PMID 31735345. Check date values in:
|date=
(help) - ↑ Gascoyne, Randy D.; et al. (2003-10-01). "ALK-positive diffuse large B-cell lymphoma is associated with Clathrin-ALK rearrangements: report of 6 cases". Blood. 102 (7): 2568–2573. doi:10.1182/blood-2003-03-0786. ISSN 0006-4971. PMID 12763927.
- ↑ Onciu, Mihaela; et al. (2003-10-01). "ALK-positive plasmablastic B-cell lymphoma with expression of the NPM-ALK fusion transcript: report of 2 cases". Blood. 102 (7): 2642–2644. doi:10.1182/blood-2003-04-1095. ISSN 0006-4971. PMID 12816858.
- ↑ Takeuchi, Kengo; et al. (2011-03). "Identification of a novel fusion, SQSTM1-ALK, in ALK-positive large B-cell lymphoma". Haematologica. 96 (3): 464–467. doi:10.3324/haematol.2010.033514. ISSN 1592-8721. PMC 3046280. PMID 21134980. Check date values in:
|date=
(help) - ↑ Lee, Seung Eun; et al. (2014-12). "Identification of RANBP2-ALK fusion in ALK positive diffuse large B-cell lymphoma". Hematological Oncology. 32 (4): 221–224. doi:10.1002/hon.2125. ISSN 1099-1069. PMID 24470379. Check date values in:
|date=
(help) - ↑ Sakamoto, Kana; et al. (2016-04). "ALK-positive large B-cell lymphoma: identification of EML4-ALK and a review of the literature focusing on the ALK immunohistochemical staining pattern". International Journal of Hematology. 103 (4): 399–408. doi:10.1007/s12185-016-1934-1. ISSN 1865-3774. PMID 26781614. Check date values in:
|date=
(help) - ↑ Ise, Mikiko; et al. (2019-02). "Identification of a novel GORASP2-ALK fusion in an ALK-positive large B-cell lymphoma". Leukemia & Lymphoma. 60 (2): 493–497. doi:10.1080/10428194.2018.1493731. ISSN 1029-2403. PMID 30187817. Check date values in:
|date=
(help) - ↑ Bedwell, Clare; et al. (2011-02). "Cytogenetically complex SEC31A-ALK fusions are recurrent in ALK-positive large B-cell lymphomas". Haematologica. 96 (2): 343–346. doi:10.3324/haematol.2010.031484. ISSN 1592-8721. PMC 3031708. PMID 21109691. Check date values in:
|date=
(help) - ↑ Valera, Alexandra; et al. (2013-10). "ALK-positive large B-cell lymphomas express a terminal B-cell differentiation program and activated STAT3 but lack MYC rearrangements". Modern Pathology: An Official Journal of the United States and Canadian Academy of Pathology, Inc. 26 (10): 1329–1337. doi:10.1038/modpathol.2013.73. ISSN 1530-0285. PMC 6368829. PMID 23599149. Check date values in:
|date=
(help)
Notes
*Primary authors will typically be those that initially create and complete the content of a page. If a subsequent user modifies the content and feels the effort put forth is of high enough significance to warrant listing in the authorship section, please contact the CCGA coordinators (contact information provided on the homepage). Additional global feedback or concerns are also welcome.